FDA Chief Scientist Schwetz May Have Larger Role Under Henney
This article was originally published in The Gray Sheet
Executive Summary
FDA Interim Chief Scientist and National Center for Toxicology Research Director Bernard Schwetz, PhD, may be in line for a more prominent role at FDA under Commissioner Jane Henney.
You may also be interested in...
FDA Senior Advisor For Science Schwetz Named Acting Deputy Commissioner
FDA Senior Advisor for Science Bernard Schwetz, PhD, will serve as acting deputy commissioner as the agency searches for a permanent appointee for the office vacated by Michael Friedman, MD.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.